Opus Genetics, Inc. (IRD) COO’s 4,644 shares sold to cover RSU tax withholding

Rhea-AI Filing Summary

Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, had 4,644 shares of common stock sold on July 23, 2026 at $2.94 per share. The shares were sold automatically to satisfy tax withholding obligations from a restricted stock unit vesting and were not a discretionary trade. Following this transaction, Schachle directly held 291,440 shares of Opus Genetics common stock.

Insider Trade Summary

Net Seller: 4,644 shares

Net Sell 1 txn

Insider SCHACHLE JOSEPH K

Role Chief Operating Officer

Sold 4,644 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	4,644	$2.94	$14K

Holdings After Transaction: Common Stock — 291,440 shares (Direct)

Footnotes (1)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 4,644 shares Sale price: $2.94 per share Shares held after transaction: 291,440 shares +1 more

4 metrics

Shares sold 4,644 shares Common stock sold on July 23, 2026 to satisfy tax withholding

Sale price $2.94 per share Price for the 4,644 common shares sold

Shares held after transaction 291,440 shares Direct common stock ownership of Joseph K. Schachle following the sale

Net shares sold 4,644 shares Net sell direction across all reported transactions in this filing

Key Terms

tax withholding obligations, vesting and settlement event, restricted stock units award, Sale in open market or private transaction

4 terms

tax withholding obligations financial

"required by the Company to satisfy tax withholding obligations that arose"

vesting and settlement event financial

"obligations that arose in connection with a vesting and settlement event"

restricted stock units award financial

"settlement event from a restricted stock units award"

Sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/27/2026 - 04:08 PM Accepted by SEC EDGAR 07/27/2026 - 04:07 PM Learn about SEC filing dates

FAQ

What insider transaction did Opus Genetics (IRD) COO Joseph K. Schachle report?

Joseph K. Schachle reported an automatic sale of 4,644 Opus Genetics common shares on July 23, 2026. The sale was executed to cover tax withholding obligations triggered by a restricted stock unit vesting, and was not a discretionary trade.

How many Opus Genetics (IRD) shares were sold and at what price?

A total of 4,644 common shares of Opus Genetics were sold at an average price of $2.94 per share. The sale was reported as a non-derivative common stock transaction and was executed to satisfy tax withholding obligations from an RSU vesting event.

Why were Opus Genetics (IRD) shares sold in this Form 4 transaction?

The shares were sold automatically to satisfy tax withholding obligations arising from a vesting and settlement event of a restricted stock units award. The footnote states this transaction does not represent a discretionary trade by COO Joseph K. Schachle.

How many Opus Genetics (IRD) shares does Joseph K. Schachle hold after the sale?

After the reported transaction, Joseph K. Schachle directly held 291,440 shares of Opus Genetics common stock. This post-transaction holding reflects his remaining direct ownership following the automatic sale of 4,644 shares for tax withholding purposes.

Was the Opus Genetics (IRD) insider sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as a plan, and the footnote explains the sale was automatically executed to cover tax withholding from RSU vesting, rather than being a discretionary or separately planned trading program.

What type of security is involved in Joseph K. Schachle’s Opus Genetics (IRD) transaction?

The transaction involves Opus Genetics common stock, reported as a non-derivative security. The sale relates to shares issued in connection with a restricted stock units award that had vested and settled, triggering associated tax withholding obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHACHLE JOSEPH K

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S(1)		4,644	D	$2.94	291,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn, by Power of Attorney	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)